Pavel L Photo and Video / Shutterstock.com
LSIPR takes a look at what the Practical Law Life Sciences Forum, due to take place on June 25, has to offer.
On Thursday, June 25, 400 private lawyers and in-house counsels from the life sciences industry will gather at the third annual Life Sciences Forum hosted by Thomson Reuters’s Practical Law. This year, the forum takes place in in the shadow of London’s St Paul’s Cathedral.
As PwC reports that the first quarter of 2015 saw the greatest ever value of mergers and acquisitions in the pharmaceutical industry, and the forthcoming EU Data Protection Regulation demands a delicate balancing act between data protection and data transparency, lawyers practicing in the life sciences industry are dealing with an evolving set of challenges.
This year’s forum aims to provide guidance on how to cope with these new challenges, from maximising the value of industry partnerships, to providing tips on how to operate in a range of jurisdictions, to informing on useful strategies to deploy throughout the lifecycle of a pharma product or medical device.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Thomson Reuters’s Practical Law, AstraZeneca, Merck, GSK, Actavis, Ranbaxy,